Redefining cancer treatment with AI and genomic data
A cloud-based decision support platform, trained on the clinical reasoning of our molecular tumor board, that turns comprehensive genomic profiling data and the latest literature into personalized treatment paths within minutes.
Interpreting complex genomic data clinically
The frontier of cancer treatment is reading each tumor's genetic map to design individualized therapy. But making sense of this data requires continuously tracking rapidly evolving literature and deep molecular oncology expertise.
Your digital decision support assistant: MDT Precision
Within MDT Molecular Decision Technologies Inc.: a cloud-based clinical decision support system trained on the real-world genomic data of more than 2,500 patients and expert curation reports. When an oncologist uploads a test result, our AI scans the literature and offers targeted alternatives with algorithms that predict treatment response and recurrence risk.
How do we train our AI?
We are not building an ordinary search engine. The platform is woven thread by thread with our expertise in bioinformatics, computational biology and precision oncology.
Real clinical data (Data Moat)
The model is trained on the genomic variants, applied treatments and clinical responses of 2,500+ patients treated at our center.
Clinical reasoning (Reasoning)
It learns the methodology our PhD-level molecular cancer biologists use to interpret data, identify active pathways and make decisions.
Smart literature review
A cloud-based infrastructure that analyzes scientific publications with advanced language models to offer clinicians evidence-based targeted treatment alternatives.
From report to treatment path, in three steps
Upload the genomic report
Comprehensive genomic profiling (CGP) or liquid biopsy test results are uploaded to a secure cloud infrastructure.
AI analyzes
Variants are interpreted, active pathways are identified, relevant literature is scanned, and treatment response & recurrence risk are predicted.
Board-quality report
Targeted treatment alternatives, generated with molecular tumor board logic and justified with evidence levels, are presented.
Let's train the model together. Early access is free for our oncologists.
We invite selected oncology specialists to voluntarily try MDT Precision in their clinical practice and share feedback. Your feedback makes our model stronger and more accurate — at the start of this partnership we offer early access free of charge.
- Free early accessFull access to the platform throughout the pilot period.
- Direct product impactYour feedback shapes the roadmap and the model.
- Board-quality second opinionFast, evidence-based support on your cases.
At the intersection of science, medicine and technology
Behind the project stands a multidisciplinary, powerful brain trust.
Prof. Dr. Mutlu Demiray
Founder of Turkey's first personalized cancer treatment center. With over 30 years of oncology experience, he has evaluated the genomic profiling tests of more than 2,500 domestic and international patients, pioneering precision oncology.
Our core team & experts
Our multidisciplinary R&D team spans software engineering, bioinformatics, data science, cancer genetics and molecular cancer biology — each contributing equally to the project.
Becoming the global decision standard in genomics-based cancer treatment
Through our R&D within Teknopol İstanbul, our goal is to build an exportable, high-value healthcare technology platform.
Target audience & market
Private hospital chains, university hospitals, molecular diagnostics laboratories and independent oncologists who want to practice personalized oncology.
Business model
A subscription-based B2B SaaS licensing model. A cloud-based, scalable platform addressing oncology specialists worldwide who use comprehensive genomic profiling.
Sustainable competitive advantage (Moat)
The biggest barrier in healthcare AI is the lack of "validated, high-quality clinical data." Our platform's greatest differentiator is that it was trained not merely as a rule-based engine from scratch, but on the CGP results of 2,500+ real patients, expert curation reports and personally validated treatment follow-ups. This creates a hard-to-imitate clinical moat and global commercial potential.
Collaboration & infrastructure